Please check your internet connection and try again.
# Dexamethasone in Chronic ITP
## Overview
Dexamethasone is a high-potency, long-acting glucocorticoid used in Immune Thrombocytopenia (ITP) for its rapid onset and ability to inhibit phagocytosis of antibody-coated platelets. It is often preferred over prednisone for initial rescue therapy or relapsed cases due to potentially shorter treatment duration and higher response rates.
## Primary Indications
* Management of acute ITP exacerbations.
* "Pulse" therapy for chronic ITP patients requiring second-line intervention or bridge therapy.
* Pre-operative management to increase platelet counts.
## Adult Dosing
* **Standard Regimen:** 40 mg orally once daily for 4 consecutive days.
* **Repeating Cycles:** Cycles may be repeated every 14 to 28 days depending on patient response and clinical status, per institutional protocol.
## Pediatric Dosing
* **Standard Regimen:** 0.6 mg/kg/day (maximum 40 mg/day) orally for 4 consecutive days.
* **Guidance:** Dosing follows protocols similar to adult pulse therapy; consult institutional guidelines for pediatric hematology-oncology standards.
## Dose Adjustments
* **Hepatic Impairment:** No specific criteria; however, monitor closely for increased glucocorticoid exposure.
* **Renal Impairment:** Generally no adjustment required.
* **Therapy Assessment:** If no response is observed after 1–2 cycles, discontinue therapy and evaluate alternative second-line options (e.g., TPO-RAs, rituximab, or splenectomy).
## Contraindications
* Systemic fungal infections.
* Known hypersensitivity to dexamethasone or components of the formulation.
* Recent or ongoing administration of live or live-attenuated vaccines (due to immunosuppression).
## Adverse Effects
* **Common:** Insomnia, mood disturbances (euphoria or depression), gastric irritation, increased appetite, fluid retention/hypertension.
* **Serious:** Hyperglycemia, increased risk of infection, avascular necrosis (less common with short pulse therapy), peptic ulcer disease, and psychiatric disturbances.
## Key Drug Interactions
* **CYP3A4 Inducers:** (e.g., rifampin, phenytoin, carbamazepine) decrease dexamethasone efficacy.
* **CYP3A4 Inhibitors:** (e.g., ketoconazole, ritonavir) may increase dexamethasone toxicity.
* **NSAIDs:** Increased risk of gastrointestinal ulceration/bleeding.
* **Anticoagulants/Antiplatelets:** Increased risk of bleeding when combined with steroid-induced gastric impact.
## Monitoring
* **Efficacy:** Serial Complete Blood Counts (CBC) with platelet count to assess response.
* **Safety:** Blood glucose (especially in diabetic patients), blood pressure, and clinical assessment for infection or occult GI bleeding.
* **Psychiatric:** Monitor for agitation or acute anxiety.
## Clinical Pearls
* **Administration:** Take with food to minimize gastric distress. Administer doses early in the day to mitigate insomnia.
* **Duration:** Pulse dexamethasone therapy is generally self-limiting (limited to 4 days); rapid tapering is often unnecessary for short courses, but clinical judgment should prevail if the patient has had prior prolonged steroid exposure.
* **Uncertainty Note:** While dexamethasone pulse therapy is well-supported, long-term outcomes ("cure" rates) in chronic ITP are variable. Response is often transient, requiring transition to long-term management strategies.
***
*Disclaimer: This information is for educational purposes and does not substitute for professional medical judgment. Always verify current prescribing information, institutional protocols, and patient-specific factors before administration.*
